Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase II Randomized, Double-blind Study to Evaluate the Safety, Neutralizing Activity and Efficacy of AZD3152 for Pre-exposure Prophylaxis of COVID-19 in Participants Having an Increased Risk for Inadequate Response to Active Immunization (NOVELLA)

NCT06057064 is registered in ClinicalTrials.gov with AstraZeneca as lead sponsor.

NCT NCT06057064
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT06057064 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase II Randomized, Double-blind Study to Evaluate the Safety, Neutralizing Activity and Efficacy of AZD3152 for Pre-exposure Prophylaxis of COVID-19 in Participants Having an Increased Risk for Inadequate Response to Active Immunization (NOVELLA)
Lead sponsor
AstraZeneca
Phase
Phase 2
Overall status
Completed
Start date
September 29, 2023
Completion date
May 17, 2024
Enrollment
116 (actual)
Sites
6

Conditions

As the registry lists them; a condition with its own page is linked.

covid-19, sars-cov-2